Reset filter
Trefwoorden
Gynecology ×
Meer tonen Trefwoorden
Inhoudsopgave
  1. 1. Clinical Trial
    1. 1.1. Eligibility Determination
    1. 1.2. Medical History
    1. 1.3. Physical Examination
    1. 1.4. Assessment Score
    1. 1.5. Apparative Diagnostics
    1. 1.6. Laboratory
    1. 1.7. Pathology/Histology
    1. 1.8. Consent
    1. 1.9. Therapy
    1. 1.10. Operative Report
    1. 1.11. Adverse Event
    1. 1.12. Follow-Up
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Geselecteerde datamodellen

U moet ingelogd zijn om meerdere datamodellen te selecteren en die te downloaden of te analyseren.

985 Zoekresultaten.
Relevantie Beoordeling Nieuwe eerst Oude eerst

Eligibility Breast Cancer, Colorectal Cancer NCT01493336

- 9/30/19 - 1 Formulier, 2 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours; ODM derived from: https://clinicaltrials.gov/show/NCT01493336

Eligibility Breast Cancer, Early Breast Cancer NCT02443467

- 1/20/17 - 1 Formulier, 2 Itemgroepen, 12 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02443467

PRIOR TREATMENT FOR METASTATIC BREAST CANCER Roche H0650g Breast Cancer - PRIOR TREATMENT FOR METASTATIC BREAST CANCER

- 3/15/21 - 1 Formulier, 2 Itemgroepen, 10 Data-elementen, 1 Taal
Itemgroepen: RADIOTHERAPY, HORMONAL THERAPY, METASTASE
Study part: Prior treatment for metastatic breast cancer. A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Eligibility Metastatic Breast Cancer, Locally Advanced Breast Cancer NCT00960960

- 6/19/18 - 1 Formulier, 2 Itemgroepen, 20 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
A Study of PI3-Kinase Inhibitor GDC-0941 in Combination With Paclitaxel, With and Without Bevacizumab or Trastuzumab, in Patients With Locally Recurrent Or Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00960960

PRIOR TREATMENT FOR BREAST CANCER (ADJUVANT SETTING) Roche H0650g Breast Cancer - PRIOR TREATMENT FOR BREAST CANCER (ADJUVANT SETTING)

- 3/15/21 - 1 Formulier, 3 Itemgroepen, 18 Data-elementen, 1 Taal
Itemgroepen: Chemotherapy, Therapeutic regimen, ADJUVANT THERAPY
Study part: Prior treatment for breast cancer (Adjuvant setting). A phase III multinational, randomized, single-blind study of recombinant humanized anti-p185HER2 monoclonal antibody (rhuMAb HER2) in patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer. "Terms of use: You may not use this document or the information contained herein to a regulatory authority in connection with an application for a marketing authorization or any other regulatory submission without the express written consent of Roche"

Eligibility Breast Cancer NCT00818051

- 9/27/21 - 1 Formulier, 1 Itemgroep, 20 Data-elementen, 1 Taal
Itemgroep: Criteria
Radiation Therapy in Treating Women Who Have Undergone Breast Conservation Surgery and Systemic Therapy for Early Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00818051

Eligibility Breast Cancer NCT01069211

- 9/27/21 - 1 Formulier, 2 Itemgroepen, 13 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Clinical Outcomes After Letrozole Treatment According to the Estrogen Receptor Expression in Postmenopausal Women; ODM derived from: https://clinicaltrials.gov/show/NCT01069211

Eligibility Breast Cancer NCT01067976

- 9/27/21 - 1 Formulier, 2 Itemgroepen, 16 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Efficacy and Safety of Gadobutrol 1.0 Molar (Gadovist) for Breast MRI; ODM derived from: https://clinicaltrials.gov/show/NCT01067976

Eligibility Breast Cancer NCT00917735

- 9/27/21 - 1 Formulier, 2 Itemgroepen, 19 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Green Tea and Reduction of Breast Cancer Risk; ODM derived from: https://clinicaltrials.gov/show/NCT00917735

Eligibility Breast Cancer NCT01917578

- 9/20/21 - 1 Formulier, 2 Itemgroepen, 19 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction; ODM derived from: https://clinicaltrials.gov/show/NCT01917578

Eligibility Breast Cancer NCT01013337

- 9/20/21 - 1 Formulier, 1 Itemgroep, 18 Data-elementen, 1 Taal
Itemgroep: Criteria
Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain; ODM derived from: https://clinicaltrials.gov/show/NCT01013337

Eligibility Breast Cancer NCT02482376

- 9/20/21 - 1 Formulier, 2 Itemgroepen, 19 Data-elementen, 1 Taal
Itemgroepen: Inclusion Criteria, Exclusion Criteria
Preoperative Single-Fraction Radiotherapy in Early Stage Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT02482376

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial